Suppr超能文献

在TNM分期系统的未来更新中,微创肺腺癌是否应从IA1期转移至0期?

Should minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system?

作者信息

Chen Tianxiang, Luo Jizhuang, Gu Haiyong, Gu Yu, Huang Jia, Luo Qingquan, Yang Yunhai

机构信息

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.

出版信息

J Thorac Dis. 2018 Nov;10(11):6247-6253. doi: 10.21037/jtd.2018.10.78.

Abstract

BACKGROUND

The 8th International Association Study of Lung Cancer (IASLC) TNM classification staging project for lung cancer has classified patients with adenocarcinoma in situ (AIS) into stage 0, while patients with a minimally invasive adenocarcinoma (MIA) were classified into stage IA1. However, MIA patients, similar to AIS patients, have an approximately a 100% 5-year survival. This study aimed to investigate if MIA could be transferred from stage IA to stage 0 in the next TNM staging system.

METHODS

We retrospectively reviewed 1,524 consecutive patients with a pathologically confirmed AIS, MIA and an invasive adenocarcinoma (IADC) in stage IA1. Disease-free survival (DFS) and overall survival (OS) were analyzed to evaluate survival difference between these three groups.

RESULTS

There were 412 AIS, 675 MIA and 437 IADC patients in stage IA1. No statistically significant differences for DFS and OS (P=0.109) were seen between the AIS and MIA groups. Patients of the IADC group had significantly worse DFS (P=0.003) but the OS rate (P=0.941) was insignificant when compared with the MIA patients. Similar survival results were seen when comparisons were made between the IADC and AIS/MIA groups. The IADC group had a worse DFS (P=0.001) rate but no OS (P=0.380) difference with the AIS/MIA groups.

CONCLUSIONS

Patients with AIS and MIA had similar post-surgical survival rates. We propose that MIA may potentially be transferred from IA1 to stage 0 in the future.

摘要

背景

第八届国际肺癌研究协会(IASLC)肺癌TNM分类分期项目已将原位腺癌(AIS)患者归类为0期,而微浸润腺癌(MIA)患者则归类为IA1期。然而,MIA患者与AIS患者相似,其5年生存率约为100%。本研究旨在探讨在未来的TNM分期系统中,MIA是否可从IA期转移至0期。

方法

我们回顾性分析了1524例经病理证实为AIS、MIA和IA1期浸润性腺癌(IADC)的连续患者。分析无病生存期(DFS)和总生存期(OS),以评估这三组患者的生存差异。

结果

IA1期有412例AIS患者、675例MIA患者和437例IADC患者。AIS组和MIA组之间的DFS和OS无统计学显著差异(P = 0.109)。与MIA患者相比,IADC组患者的DFS显著更差(P = 0.003),但OS率(P = 0.941)无显著差异。IADC组与AIS/MIA组比较时也观察到类似的生存结果。IADC组与AIS/MIA组相比,DFS率更差(P = 0.001),但OS无差异(P = 0.380)。

结论

AIS和MIA患者术后生存率相似。我们建议未来MIA可能会从IA1期转移至0期。

相似文献

引用本文的文献

5
Molecular biomarkers in early stage lung cancer.早期肺癌中的分子生物标志物
Transl Lung Cancer Res. 2021 Feb;10(2):1165-1185. doi: 10.21037/tlcr-20-750.

本文引用的文献

10
Non-Small Cell Lung Cancer, Version 6.2015.非小细胞肺癌临床实践指南(2015 年第 6 版)
J Natl Compr Canc Netw. 2015 May;13(5):515-24. doi: 10.6004/jnccn.2015.0071.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验